Physicians' Academy for Cardiovascular Education

New fully human PCSK9 antibody successful in phase 2 trial

Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease

(from the Phase 2 EQUATOR Study)

Literature - Baruch A, Mosesova S, Davis JD, et al. - Am J Cardiol. 2017 Mar 1, Epub ahead of print

Main results

Conclusion

RG7652 significantly reduced LDL-c levels as well as ApoB and Lp(a) in high-risk CHD patients. The magnitude and duration of LDL-c-lowering were dose-dependent. On the other hand, RG7652 did not lower inflammatory markers and cytokines, suggesting that PCSK9 inhibition does not have the same effect on systemic inflammation as statins. Furthermore, no concerning AEs were experienced.

References

Show references

Download PPT slides Find this article online at Am J Cardiol

New fully human PCSK9 antibody successful in phase 2 trial

Share this page with your colleagues and friends: